Prediction of ARrhythmic Events With Positron Emission Tomography II (PAREPET II)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
Sudden cardiac death continues to be a major contributor to mortality in patients with ischemic cardiomyopathy. While implantable defibrillators can prevent death from ventricular arrhythmias, our current approach to identify patients at highest risk primarily rests on demonstrating a reduction in left ventricular ejection fraction less than 35%. The purpose of this observational cohort study is to prospectively test whether this can be enhanced by quantifying the amount of sympathetic denervation, left ventricular end-diastolic volume or brain natriuretic peptide levels.
Diagnostic Test: PET scan quantifying sympathetic denervation using [18F]-LMI1195
Using current guidelines based primarily on ejection fraction (EF), only one-quarter of patients receiving an implantable cardiac defibrillator (ICD) for the primary prevention of sudden cardiac arrest (SCA) require appropriate ICD therapy within 5 years. The NIH-sponsored PAREPET study (Prediction of ARrhythmic Events with Positron Emission Tomography, ClinicalTrials.gov, NCT01400334) identified four independent risk factors that predict SCA or ICD equivalent in patients with ischemic cardiomyopathy. Using retrospectively defined cut-points, the absence of these risk factors identified 38% of the cohort with a very low risk of SCA (<1% per year). This rate is actually lower than the 1.5-2% annual rate of SCA among patients with coronary artery disease and mild left ventricular (LV) dysfunction, who are not considered candidates for a primary prevention ICD. This proposal will prospectively determine whether these risk factors can form the basis of a clinically applicable approach to identify a subgroup of patients who are candidates for an ICD, but are at low enough risk of SCA to have an ICD safely withheld. Our long-term goal is to develop better approaches to identify patients with coronary artery disease who are most likely to benefit from prevention of SCA with placement of an implantable defibrillator.
Sudden Cardiac Arrest Events [ Time Frame: Through study completion, an average of 3 years ]
The primary end-point will be SCA or ICD equivalent as used in PAREPET. This will consist of ICD therapies for ventricular fibrillation or ventricular tachycardia >240 bpm, and adjudicated arrhythmic death using the modified Hinkle-Thaler criteria.
Other Outcome Measures:
All cause cardiac mortality [ Time Frame: Through study completion, an average of 3 years ]
Adjudicated total cardiac mortality (SCA + non-sudden cardiac death).
All appropriate ICD therapies [ Time Frame: Through study completion, an average of 3 years ]
Adjudicated appropriate ICD therapies (ICD shock and anti-tachycardia pacing) for ventricular arrhythmias. Appropriate ICD therapies will be determined from ICD device interrogation.
Hospitalization for heart failure and myocardial infarction. [ Time Frame: Through study completion, an average of 3 years ]
Interval hospitalizations for heart failure or myocardial infarction will be assessed via phone follow-up at 3 month intervals. Subjects having either will be invited to return for a repeat PET scan, echocardiogram and serum sampling to assess whether the underlying substrate for arrhythmogenesis has changed.
Biospecimen Retention: Samples Without DNA
Serum and plasma samples will be obtained for protein biomarkers indicating increased risk of arrhythmias including brain natriuretic peptide levels.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
The study population comprises adult patients of either sex with ischemic cardiomyopathy who have an ejection fraction ≤ 35% and New York Heart Association Class II or III CHF or an ejection fraction ≤ 30% and Class I CHF who are candidates to place an ICD for the primary prevention of SCA. Subjects already having a primary prevention ICD are eligible if they have not yet received an appropriate ICD shock for ventricular arrhythmias.
Coronary artery disease (by cardiac catheterization or definite myocardial infarction)
ICD implantation for the primary prevention of SCA
Medical therapy including beta-blockers and angiotensin inhibition therapy [angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor antagonist (ARA)].
Plans for coronary revascularization (due to the independent impact on SCA)
Contraindication for PET (i.e. claustrophobia, pregnancy, physical limitation)
Tricyclic antidepressant use (inhibits norepinephrine and LMI1195 uptake)
Comorbidities limiting life expectancy <2yr.
Age <18 years or inability to provide informed consent